Thailand Breaks Merck's Patent For AIDS Drug

Law360, New York (December 4, 2006, 12:00 AM EST) -- Going over the heads of big pharmaceutical companies, Thailand has issued the first compulsory license for a generic version of Merck & Co Inc.’s HIV-AIDS drug Efavirenz in an effort to lower costs.

Efavirenz is used as part of antiretroviral therapy for the treatment of HIV-AIDs, usually in conjunction with other HIV-AIDS drugs. The Thai government already uses other off-patent drugs to treat AIDS patients, but as patients live longer and require more advanced therapies, drug costs have skyrocketed.

Thailand’s state-owned pharmaceutical manufacturer, the Government Pharmaceutical...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.